Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patie
The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:
- The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:
MT-6402 acts uniquely from other approved checkpoint agents. - MT-6402 depletes immunosuppressive PD-L1+ immune cells and tumor cells, activates a T-effector phenotype, and remodels the tumor microenvironment to restore T-cell surveillance of the tumor.
- An early monotherapy efficacy signal in head and neck squamous cell carcinoma (HNSCC) was identified.
- The patients remain on study at cycles 19 and 10, respectively (one cycle = 4 weeks), demonstrating the potential for durable monotherapy activity with MT-6402.